Shopping Cart 0
Cart Subtotal
USD 0

Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin's Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

JW Therapeutics Raises USD90 Million in Series A Financing 16

AbViro Raises USD0.4 Million in Venture Financing 17

Juno Therapeutics Raises USD134 Million in Series B Financing 18

Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19

Juno Therapeutics Raises USD 145 Million In Series A Financing 20

AbVitro Raises USD 0.75 Million In Venture Financing 22

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23

X-BODY Raises Additional USD 0.6 Million In Venture Financing 24

Partnerships 25

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25

Juno Therapeutics Forms Joint Venture with WuXi AppTec 26

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27

Celgene Exercises Option Agreement with Juno Therapeutics 28

Juno Therapeutics Enters into Research Agreement with Editas Medicine 29

MedImmune Enters into Agreement with Juno Therapeutics 30

Juno Therapeutics Enters into Research Agreement with FHCRC 31

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32

Licensing Agreements 33

Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33

Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34

Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35

Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41

Vernalis Enters into Licensing Agreement with RedoxTherapies 42

Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44

Juno Therapeutics Enters into Licensing Agreement with FHCRC 45

Juno Therapeutics Enters into Licensing Agreement with Trianni 46

Celgene Enters into Licensing Agreement with Juno Therapeutics 47

Equity Offering 48

Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48

Juno Therapeutics Raises USD304 Million in IPO 50

Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52

Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53

Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54

Asset Transactions 55

Roche Acquires PETE Technology from AbVitro 55

Acquisition 56

Celgene Acquires Juno Therapeutics for USD9 Billion 56

Juno Therapeutics Acquires RedoxTherapies 58

Juno Therapeutics Acquires AbVitro 59

Juno Therapeutics Acquires X-BODY 60

AstraZeneca May Acquire Juno Therapeutics 61

Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62

Juno Therapeutics Acquires ZetaRx BioSciences 63

Juno Therapeutics Inc-Key Competitors 64

Juno Therapeutics Inc-Key Employees 65

Juno Therapeutics Inc-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Joint Venture 66

Recent Developments 67

Strategy And Business Planning 67

Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 67

Financial Announcements 68

Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 68

Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 71

May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results 73

Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 75

Corporate Communications 79

Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 79

Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 80

May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors 81

Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 82

Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 83

Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 84

Legal and Regulatory 85

Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc.-JUNO 85

Government and Public Interest 86

Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 86

Product News 87

12/12/2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH 87

12/09/2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL 89

11/01/2017: Juno Therapeutics to Highlight New Advances of Anti-Neoplastic Drug Candidate JCARH125 at ASH Conference 90

Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects 92

06/05/2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma 94

Clinical Trials 96

Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma 96

Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference 98

Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma 100

May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 102

May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy 103

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

JW Therapeutics Raises USD90 Million in Series A Financing 16

AbViro Raises USD0.4 Million in Venture Financing 17

Juno Therapeutics Raises USD134 Million in Series B Financing 18

Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19

Juno Therapeutics Raises USD 145 Million In Series A Financing 20

AbVitro Raises USD 0.75 Million In Venture Financing 22

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23

X-BODY Raises Additional USD 0.6 Million In Venture Financing 24

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25

Juno Therapeutics Forms Joint Venture with WuXi AppTec 26

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27

Celgene Exercises Option Agreement with Juno Therapeutics 28

Juno Therapeutics Enters into Research Agreement with Editas Medicine 29

MedImmune Enters into Agreement with Juno Therapeutics 30

Juno Therapeutics Enters into Research Agreement with FHCRC 31

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32

Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33

Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34

Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35

Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41

Vernalis Enters into Licensing Agreement with RedoxTherapies 42

Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44

Juno Therapeutics Enters into Licensing Agreement with FHCRC 45

Juno Therapeutics Enters into Licensing Agreement with Trianni 46

Celgene Enters into Licensing Agreement with Juno Therapeutics 47

Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48

Juno Therapeutics Raises USD304 Million in IPO 50

Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52

Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53

Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54

Roche Acquires PETE Technology from AbVitro 55

Celgene Acquires Juno Therapeutics for USD9 Billion 56

Juno Therapeutics Acquires RedoxTherapies 58

Juno Therapeutics Acquires AbVitro 59

Juno Therapeutics Acquires X-BODY 60

AstraZeneca May Acquire Juno Therapeutics 61

Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62

Juno Therapeutics Acquires ZetaRx BioSciences 63

Juno Therapeutics Inc, Key Competitors 64

Juno Therapeutics Inc, Key Employees 65

Juno Therapeutics Inc, Subsidiaries 66

Juno Therapeutics Inc, Joint Venture 66

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Summary

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin's Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

JW Therapeutics Raises USD90 Million in Series A Financing 16

AbViro Raises USD0.4 Million in Venture Financing 17

Juno Therapeutics Raises USD134 Million in Series B Financing 18

Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19

Juno Therapeutics Raises USD 145 Million In Series A Financing 20

AbVitro Raises USD 0.75 Million In Venture Financing 22

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23

X-BODY Raises Additional USD 0.6 Million In Venture Financing 24

Partnerships 25

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25

Juno Therapeutics Forms Joint Venture with WuXi AppTec 26

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27

Celgene Exercises Option Agreement with Juno Therapeutics 28

Juno Therapeutics Enters into Research Agreement with Editas Medicine 29

MedImmune Enters into Agreement with Juno Therapeutics 30

Juno Therapeutics Enters into Research Agreement with FHCRC 31

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32

Licensing Agreements 33

Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33

Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34

Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35

Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41

Vernalis Enters into Licensing Agreement with RedoxTherapies 42

Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44

Juno Therapeutics Enters into Licensing Agreement with FHCRC 45

Juno Therapeutics Enters into Licensing Agreement with Trianni 46

Celgene Enters into Licensing Agreement with Juno Therapeutics 47

Equity Offering 48

Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48

Juno Therapeutics Raises USD304 Million in IPO 50

Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52

Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53

Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54

Asset Transactions 55

Roche Acquires PETE Technology from AbVitro 55

Acquisition 56

Celgene Acquires Juno Therapeutics for USD9 Billion 56

Juno Therapeutics Acquires RedoxTherapies 58

Juno Therapeutics Acquires AbVitro 59

Juno Therapeutics Acquires X-BODY 60

AstraZeneca May Acquire Juno Therapeutics 61

Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62

Juno Therapeutics Acquires ZetaRx BioSciences 63

Juno Therapeutics Inc-Key Competitors 64

Juno Therapeutics Inc-Key Employees 65

Juno Therapeutics Inc-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Joint Venture 66

Recent Developments 67

Strategy And Business Planning 67

Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 67

Financial Announcements 68

Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 68

Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 71

May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results 73

Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 75

Corporate Communications 79

Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 79

Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 80

May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors 81

Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 82

Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 83

Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 84

Legal and Regulatory 85

Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc.-JUNO 85

Government and Public Interest 86

Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 86

Product News 87

12/12/2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH 87

12/09/2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL 89

11/01/2017: Juno Therapeutics to Highlight New Advances of Anti-Neoplastic Drug Candidate JCARH125 at ASH Conference 90

Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects 92

06/05/2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma 94

Clinical Trials 96

Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma 96

Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference 98

Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma 100

May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 102

May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy 103

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Juno Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Juno Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

JW Therapeutics Raises USD90 Million in Series A Financing 16

AbViro Raises USD0.4 Million in Venture Financing 17

Juno Therapeutics Raises USD134 Million in Series B Financing 18

Juno Therapeutics Raises USD 31 Million In Extended Series A Financing 19

Juno Therapeutics Raises USD 145 Million In Series A Financing 20

AbVitro Raises USD 0.75 Million In Venture Financing 22

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 23

X-BODY Raises Additional USD 0.6 Million In Venture Financing 24

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 25

Juno Therapeutics Forms Joint Venture with WuXi AppTec 26

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 27

Celgene Exercises Option Agreement with Juno Therapeutics 28

Juno Therapeutics Enters into Research Agreement with Editas Medicine 29

MedImmune Enters into Agreement with Juno Therapeutics 30

Juno Therapeutics Enters into Research Agreement with FHCRC 31

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 32

Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 33

Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 34

Juno Therapeutics Enters into Licensing Agreement with Oncotracker 35

Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 36

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 37

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 38

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 39

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 41

Vernalis Enters into Licensing Agreement with RedoxTherapies 42

Juno Therapeutics Enters into Licensing Agreement with St. Jude Children's Research Hospital 43

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 44

Juno Therapeutics Enters into Licensing Agreement with FHCRC 45

Juno Therapeutics Enters into Licensing Agreement with Trianni 46

Celgene Enters into Licensing Agreement with Juno Therapeutics 47

Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 48

Juno Therapeutics Raises USD304 Million in IPO 50

Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 52

Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 53

Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 54

Roche Acquires PETE Technology from AbVitro 55

Celgene Acquires Juno Therapeutics for USD9 Billion 56

Juno Therapeutics Acquires RedoxTherapies 58

Juno Therapeutics Acquires AbVitro 59

Juno Therapeutics Acquires X-BODY 60

AstraZeneca May Acquire Juno Therapeutics 61

Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 62

Juno Therapeutics Acquires ZetaRx BioSciences 63

Juno Therapeutics Inc, Key Competitors 64

Juno Therapeutics Inc, Key Employees 65

Juno Therapeutics Inc, Subsidiaries 66

Juno Therapeutics Inc, Joint Venture 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com
chat_bubbleLet's Chat